newsfilter
← Latest News
PR Newswire·

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) extended its review timeline of the Biologics License...